Abstract
New approaches to atherosclerosis-related diseases include novel uses of proven treatments and development of innovative agents. Several commonly used cardiovascular drugs such as dihydropyridine calcium antagonists, ACE inhibitors containing the sulphydryl group, or highly lipophilic beta-blockers have some antiatherosclerotic activities. Moreover, new clinical trials suggesting that additional reduction of lowdensity lipoprotein cholesterol levels with statin therapy results in additional benefit in coronary heart disease prevention. Notably, new cholesterol transport or bile acid transport inhibitors have been found to produce significant reductions in intestinal cholesterol absorption and experimental atherosclerosis. Inhibitors of acyl coenzyme A:cholesterol acyltransferase, which can reduce cholesterol storage in macrophages and in arterial lesions, have also been developed. Finally, newer therapeutical strategies against atherogenesis may include the use of antioxidants and cholestyramine during pregnancy or the development of metalloproteinase inhibitors.
Keywords: atherosclerosis, statins, ace-inhibitors, antioxidants
Current Medicinal Chemistry
Title: New Trends in Anti-Atherosclerotic Agents
Volume: 12 Issue: 15
Author(s): C. Napoli, V. Sica, O. Pignalosa and F. de Nigris
Affiliation:
Keywords: atherosclerosis, statins, ace-inhibitors, antioxidants
Abstract: New approaches to atherosclerosis-related diseases include novel uses of proven treatments and development of innovative agents. Several commonly used cardiovascular drugs such as dihydropyridine calcium antagonists, ACE inhibitors containing the sulphydryl group, or highly lipophilic beta-blockers have some antiatherosclerotic activities. Moreover, new clinical trials suggesting that additional reduction of lowdensity lipoprotein cholesterol levels with statin therapy results in additional benefit in coronary heart disease prevention. Notably, new cholesterol transport or bile acid transport inhibitors have been found to produce significant reductions in intestinal cholesterol absorption and experimental atherosclerosis. Inhibitors of acyl coenzyme A:cholesterol acyltransferase, which can reduce cholesterol storage in macrophages and in arterial lesions, have also been developed. Finally, newer therapeutical strategies against atherogenesis may include the use of antioxidants and cholestyramine during pregnancy or the development of metalloproteinase inhibitors.
Export Options
About this article
Cite this article as:
Napoli C., Sica V., Pignalosa O. and Nigris de F., New Trends in Anti-Atherosclerotic Agents, Current Medicinal Chemistry 2005; 12 (15) . https://dx.doi.org/10.2174/0929867054367257
DOI https://dx.doi.org/10.2174/0929867054367257 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Characterizing the Binding of Angiotensin Converting Enzyme I Inhibitory Peptide to Human Hemoglobin: Influence of Electromagnetic Fields
Protein & Peptide Letters Hypercholesterolemia and Endothelium Dysfunction: Role of Dietary Supplementation as Vascular Protective Agents
Current Vascular Pharmacology 24-Hour Blood Pressure Control – A Predictor for Clinical Outcomes
Current Hypertension Reviews Current Therapeutic Approaches in Inflammatory Bowel Disease
Current Pharmaceutical Design Herbal Medicine for Anxiety, Depression and Insomnia
Current Neuropharmacology Serotonin and Obesity
Current Medicinal Chemistry - Central Nervous System Agents The Prothrombotic State in Hypertension and the Effects of Antihypertensive Treatment
Current Pharmaceutical Design Cardioprotection Acquired Through Exercise: The Role of Ischemic Preconditioning
Current Cardiology Reviews Relationship Between the Pharmacokinetics of Levosimendan and Its Effects on Cardiovascular System
Current Drug Metabolism Telomere Length Variations in Aging and Age-Related Diseases
Current Aging Science Angiotensin Converting Enzyme Inhibitory Peptides Derived from Food Proteins: Biochemistry, Bioactivity and Production
Current Pharmaceutical Design Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Crosstalk Signalling Role in Modulation of Drugs Side Effects
Current Molecular Pharmacology MRI Abnormalities Associated with Mild Cognitive Impairments of Vascular (VMCI) Versus Neurodegenerative (NMCI) Types Prodromal for Vascular and Alzheimers Dementias
Current Alzheimer Research Lifestyle Changes and Pharmacological Risk Factor Modification for Effective Vascular Disease Prevention
Vascular Disease Prevention (Discontinued) Cellular Localisation of Chromogranins and Processed Products in the Diffuse Neuroendocrine System and Related Tumours
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Mineralocorticoid Receptor Blockade in the Protection of Target Organ Damage
Cardiovascular & Hematological Agents in Medicinal Chemistry The Effects of Creatine Supplementation and Physical Exercise on Traumatic Brain Injury
Mini-Reviews in Medicinal Chemistry Virulence Potential of Staphylococcus aureus Strains Isolated from Diabetic Foot Ulcers Among Patients from Southern Poland
Current Vascular Pharmacology Cardiac Specific Overexpression of hHole Attenuates Isoproterenol–Induced Hypertrophic Remodeling through Inhibition of Extracellular Signal-Regulated Kinases (ERKs) Signalling
Current Molecular Medicine